• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Menopausal Disorders - Pipeline Review, H2 2012 Product Image

Menopausal Disorders - Pipeline Review, H2 2012

  • ID: 2245145
  • September 2012
  • 99 pages
  • Global Markets Direct

Menopausal Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Menopausal Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders. Menopausal Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Menopausal Disorders.
- A review of the Menopausal Disorders products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Menopausal Disorders Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Menopausal Disorders 10
Menopausal Disorders Therapeutics under Development by Companies 12
Menopausal Disorders Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Menopausal Disorders Therapeutics – Products under Development by Companies 20
Menopausal Disorders Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Menopausal Disorders Therapeutics Development 22
Eisai Co., Ltd. 22
Noven Pharmaceuticals, Inc. 23
Pfizer Inc. 24
Paladin Labs Inc. 25
Bionovo, Inc. 26
Pantarhei Bioscience BV 27
PharmaNova Inc. 28
EndoCeutics, Inc. 29
Pherin Pharmaceuticals, Inc. 30
Ausio Pharmaceuticals, LLC 31
Menopausal Disorders – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
gabapentin ER - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
gabapentin ER - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
paroxetine mesylate - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RAD-1901 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E-4 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
E-4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Estradiol + Testosterone Gel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
liquiritigenin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Aprela - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Aprela - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AUS-131 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Acupuncture + Gabapentin - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
estradiol + hydroxyprogesterone caproate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Cyclophosphamide + Goserelin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pregabalin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
megestrol acetate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cimicifuga - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
citalopram hydrobromide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ulipristal - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
micronized progesterone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Estradiol + Progesterone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Estradiol + Estriol + Progesterone - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Estradiol + Medroxyprogesterone acetate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Danggui Buxue Tang - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
estradiol - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PH-80HF - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
gabapentin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
BLACE - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Femivia - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Menopausal Disorders Therapeutics – Drug Profile Updates 80
Menopausal Disorders Therapeutics – Discontinued Products 89
Menopausal Disorders Therapeutics - Dormant Products 90
Menopausal Disorders – Product Development Milestones 91
Featured News & Press Releases 91
Aug 29, 2012: Noven Submits New Drug Application For Investigational Non-Hormonal Therapy For Menopausal Vasomotor Symptoms 91
Aug 28, 2012: Eaton Scientific Announces Clinical Trial Plans For Tropine 3 For Treatment Of Hot Flashes In Menopausal Women 91
Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures 92
Jul 31, 2012: Depomed Announces Submission Of Serada New Drug Application 93
Jul 19, 2012: EMA Accepts Regulatory Submission For Pfizer's Bazedoxifene/Conjugated Estrogens For Treatment Of Symptoms Associated With Menopause And Osteoporosis 93
Apr 17, 2012: Depomed Intends To File NDA For Serada For Treatment Of Menopausal Hot Flashes 94
Mar 28, 2012: Bionovo's Independent Data Safety Monitoring Board Recommends Continuation Of Phase III Study For Menerba 94
Mar 20, 2012: Noven Completes Phase III Clinical Program For Investigational Non-Hormonal Therapy To Treat Menopausal Vasomotor Symptoms 95
Dec 22, 2011: Noven Announces Phase III Results For Investigational Non-Hormonal Therapy For Vasomotor Symptoms 96
Nov 16, 2011: Bionovo To Begin Dosing In Menerba Phase III Clinical Trial For Menopausal Hot Flashes 96
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Tables
Number of Products Under Development for Menopausal Disorders, H2 2012 10
Products under Development for Menopausal Disorders – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Eisai Co., Ltd., H2 2012 22
Noven Pharmaceuticals, Inc., H2 2012 23
Pfizer Inc., H2 2012 24
Paladin Labs Inc., H2 2012 25
Bionovo, Inc., H2 2012 26
Pantarhei Bioscience BV, H2 2012 27
PharmaNova Inc., H2 2012 28
EndoCeutics, Inc., H2 2012 29
Pherin Pharmaceuticals, Inc., H2 2012 30
Ausio Pharmaceuticals, LLC, H2 2012 31
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 37
Menopausal Disorders Therapeutics – Drug Profile Updates 80
Menopausal Disorders Therapeutics – Discontinued Products 89
Menopausal Disorders Therapeutics – Dormant Products 90

List of Figures
Number of Products under Development for Menopausal Disorders, H2 2012 10
Products under Development for Menopausal Disorders – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 32
Assessment by Combination Products, H2 2012 33
Assessment by Route of Administration, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 35
Assessment by Molecule Type, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 37

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos